Reports and Surveys | January 22, 2026
We conducted a cost-benefit analysis of glucagon-like peptide-1 agonists (GLP-1s) using data from SHAPE, our proprietary health data warehouse. We looked at utilization of GLP-1s for both diabetes and weight loss and the impact on health plans.
Get the infographic to see the results of our analysis.
You can use SHAPE data to benchmark your plan’s experience and performance.
SHAPE includes information from large health plans across the United States representing a range of industries and organizations. Collectively, they cover more than four million lives.

Let’s have a conversation.
Get in Touch
Health, Multiemployer Plans, Public Sector, Healthcare Industry, Higher Education, Architecture Engineering & Construction, Pharmaceutical, Corporate, Well-Being
Health, Benefits Administration, Multiemployer Plans, Public Sector, Healthcare Industry, Higher Education, Architecture Engineering & Construction, Pharmaceutical, Corporate, Healthcare Cost Management
Health, Multiemployer Plans, Public Sector, Healthcare Industry, Higher Education, Architecture Engineering & Construction, Pharmaceutical, Corporate, Healthcare Cost Management
This page is for informational purposes only and does not constitute legal, tax or investment advice. You are encouraged to discuss the issues raised here with your legal, tax and other advisors before determining how the issues apply to your specific situations.
© 2026 by The Segal Group, Inc.Terms & Conditions Privacy Policy Style Guide California Residents Sitemap Disclosure of Compensation Required Notices